Regeneron and CytomX extend cancer therapy partnership to $4bn deal

​Regeneron Pharmaceuticals and CytomX have expanded their research and licensing partnership to develop conditionally activated bispecific antibody cancer therapies.

The post Regeneron and CytomX extend cancer therapy partnership to $4bn deal appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.